Hypokalemia Management Patents - 2019 & new 2020 | CORT Message Board Posts

Corcept Therapeutics Inc

  CORT website
  • TECH UPDATE: Please accept our apologies for the delay in getting our "board visit & message view" counts to normalize. As you may have noticed, starting yesterday the "board stats" for individual message boards started to display clearly erroneous "member" and "guest" visit counts. Needless to say, we don't like having unreliable traffic stats on the site any more than you do. Please understand this was not by design or intention. It's a glitch that resulted from an apparent incompatibility with the legacy code and the recent deployment of new servers to tackle issues related to last month's outage. In order to give our web developer a chance to take a closer look at the glitch and come up with a viable solution, we have decided to leave the code up for now so she can have real-world data to work with (rather than just turn the counts off again). So it looks like we may have to live with these bad counts a little longer, but our expectation is to have this resolved by early next week, if not sooner. We appreciate your patience and understanding.  

CORT   /  Message Board  /  Read Message



Rec'd By
Authored By
Minimum Recs
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  3309 of 3333  at  9/24/2020 11:29:00 AM  by


The following message was updated on 9/24/2020 11:30:33 AM.

Hypokalemia Management Patents - 2019 & new 2020

 Corcept may have another arrow in its quiver to potentially use against Teva and the other generics.
This has to do with two issued patents 10,314,850 (issued 3-2019) and an new follow-up to that 10,780,097 (issued 9-2020).
The first tilted Use of ACTH in assessment  and treatment of Hypokalemia in Cushing's patients and the second titled "Use of Cortisol in Assessment and Treatment of Hypokalemia in Cushing's Patients.
Hypokalemia is a common (1/3 +) issue that needs to be managed and thus the use of lab test for ACTH and/or Cortisol in better able to asses and manage that serious side-effect is directly relevant to the use of Mife or other GR modulators for Cushing's.
I wonder what the litigation strategy will be -- so far Corcept has not asserted these patents in the case against the generics Teva or Sun. 

     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 4     Views: 186
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Msg # Subject Author Recs Date Posted
3310 Re: Hypokalemia Management Patents - 2019 & new 2020 KJDedge 0 9/24/2020 4:07:15 PM

Financial Market Data provided by